Reading FDA GRAS notices for precision fermentation proteins
Precision fermentation uses an engineered microorganism — usually a yeast such as Komagataella phaffii (formerly Pichia pastoris) or a filamentous fungus such as Trichoderma reesei — to secrete a single target protein that was originally found in milk, eggs, meat or a sweet-tasting fruit. In the United States, most of these ingredients reach the market through the voluntary GRAS (Generally Recognized as Safe) notification program run by FDA's Human Foods Program rather than through a food additive petition.
Why the GRAS inventory is hard to use for this sector
FDA publishes every filed notice in its GRAS Notice Inventory, identified by a GRN number. The inventory describes each substance in free text, but it is not tagged by production method. A recombinant β-lactoglobulin sits next to plant extracts, fibres and probiotic strains, and the host organism only appears inside the substance description or the notice document itself. Producing a clean view of the precision fermentation pipeline therefore means reading each entry and separating recombinant food proteins from the much larger group of fermentation-derived enzymes and processing aids.
What a notice record tells you
| Element | Why it matters |
|---|---|
| GRN number | Stable reference used in FDA letters, investor materials and later resubmissions. |
| Substance and host strain | Identifies the protein and the production organism; a new host or strain usually requires its own notice. |
| Intended use | The food categories and use levels the safety conclusion covers. Uses outside that scope are not covered by the letter. |
| Notifier | The company that filed — sometimes a contract manufacturer or ingredient partner rather than the consumer brand. |
| FDA response | “No questions”, “ceased to evaluate at the notifier's request”, or “does not provide a basis”; pending notices have no letter yet. |
Protein classes seen in the inventory
- Whey proteins — β-lactoglobulin and α-lactalbumin produced in fungi or yeast, aimed at sports nutrition, beverages and dairy analogues.
- Caseins — αS1-, β- and κ-casein, which are needed to form micelles for cheese-like texture; several casein notices are still listed as pending.
- Egg proteins — ovalbumin, ovomucoid and soluble egg-white protein for baking, binding and clear beverages.
- Bioactive milk proteins — lactoferrin, where use levels are low and the price per kilogram is high.
- Heme proteins — soy leghemoglobin and myoglobin used for colour and flavour in meat analogues; colour uses may also need a color additive listing.
- Sweet proteins — brazzein, thaumatin and monellin variants intended as high-intensity sweeteners.
Due diligence points
- Match the exact strain and intended use in the notice to the product you plan to source or invest in; a “no questions” letter does not transfer to a different host or process.
- Check whether the notice is a resubmission of an earlier GRN, which often signals that FDA raised questions the first time.
- Look at the date of closure and the FDA response together: a notice that ceased to be evaluated, or is still pending, gives a partner no FDA letter to rely on.
- Remember that GRAS status covers the United States only; the EU and UK treat these proteins as novel foods that need a separate authorisation, and other markets run their own reviews.
A GRAS “no questions” letter is FDA's response to the notifier's own safety conclusion. It is not an approval, and it does not cover labelling, allergen declarations or claims.